Search

Jemma Wadham analyses the ever-changing glaciers of the Arctic.

Rebeca Gonçalves explains how plant food could be grown on the red planet.

This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

Shadi Farhangrazi describes how she accidentally became a chief executive.

We bring together recent therapy and technology features, based upon some of March's largest biopharma deals.

Applications are now open for The Spinoff Prize — a new award for early stage university spinoff companies from around the world!

In a week that was relatively quiet for dealmaking compared to many others this year, there were still two high-value deals in the CNS space, which continues to generate deals and funding despite recent clinical failures in the area.

Two major M&A deals announced today could boost hopes for a spike in dealmaking activity.

As we take our first steps into February, dealmaking activity has quietened down from the boom in recent weeks, but there was still another major M&A announced.

Continuing the recent flurry of major neuroscience deals, last week saw another one—between Celgene and Prothena.

Competition for promising investigational drugs remains fierce, with many assets snapped up before they have even started clinical trials. With the annual JP Morgan conference— typically an event where major deals are announced — now in progress, here we highlight some of the most valuable assets that are currently unpartnered, using data provided by EvaluatePharma.

Whilst many of the world’s infectious diseases are managed well due to advances in scientific research, drug-resistant bacterial infections and emerging pathogenic viruses such as Zika still continue to pose major and pressing threats to public health.

The past week has seen a couple of 1-billion-dollar deals. First, Janssen signed a potential $1 billion deal with Theravance.

This week, deals are announced by Eisai, Roivant and Sanofi amongst others.

The week’s announcements began with news from AstraZeneca.

The past week has seen another major M&A deal for the year and it’s not even the end of January.

Last week saw two major deals in neuroscience, supporting analysts’ optimism about the field, despite Pfizer’s recent exit.

Next-generation immuno-oncology targets continue to catalyze major deals, exemplified by the race to develop inhibitors of the immune checkpoint TIGIT.

Our monthly round up of key biopharma business stories from across Springer Nature’s portfolio of journals, including the latest on COVID-19 vaccines and a focus on oncology.

We present a round up of selected biopharma, biotechnology and drug discovery stories published in September 2021 across the Springer Nature portfolio of journals.

Welcome to our May selection of key business of science stories from across Springer Nature’s portfolio of journals. This month we explore some stories based around COVID vaccines and bring to you the first two series of a Nature Careers ‘Business of Science’ podcast that aims to teach new entrepreneurs the first steps of research commercialization and patenting.

Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.

Welcome to our latest round up of key business of science stories from across Springer Nature’s portfolio of journals. This month we look at how biotech funding flourished during the pandemic, and explore the latest information regarding both AstraZeneca’s and Johnson & Johnson’s vaccines in the rollout against COVID-19.

We round up the key biopharma, biotechnology and drug discovery stories that were published in July and August 2021 across the Springer Nature portfolio of journals.

Biopharma Dealmakers’ monthly round-up explores the most significant biopharma deals of the previous month.

In the largest deal of the month and the second largest M&A of the year, AbbVie announced its $63 billion acquisition of Allergan.

July and August saw a handful of high-value deals during what is usually a quiet time for dealmaking. In the most valuable deal in this period and also one of the largest this year, Amgen paid Celgene $13.4 billion for Otezla, an oral psoriasis therapy.

COVID vaccine news dominates our last monthly round-up of articles from Springer Nature research journals, magazines and supplements of the year. The articles explore how the many vaccines in development are affecting the pharmaceutical sector and what challenges lie ahead for their rollout.

From the $59 billion Shire acquisition by Takeda, to the $800 million that United Therapeutics paid upfront for Arena’s pulmonary arterial hypertension drug candidate ralinepag, 2018 was a year punctuated by product and company valuations that sometimes seemed out of sync with reality. Evaluate's Jon Moser and Paul Verdin explore the landscape of high-value unpartnered assets.

A handful of notable acquisitions took place in May, bringing in assets and platforms for major biopharma companies.

We bring together recent therapy and technology features, based upon some of January's largest biopharma deals.

We bring together recent therapy and technology features, based upon some of February's largest biopharma deals.

A string of billion dollar deals, many focused on the development of oncology therapeutics, rounded off an extraordinary year.

In our first monthly round up of the year we explore the big stories from 2020, including key biopharma deals, FDA approvals and IPOs, as well as the extraordinary impact of COVID-19 on science throughout an unusual 12 months.

Biopharma Dealmakers’ monthly round-up continues exploring the most significant biopharma deals of the previous month.

In the first of a new monthly digest, we highlight recent ‘business of science’ articles from Springer Nature research journals, magazines and supplements. This digest looks at the latest drugs approved by the US FDA and a $1bn antibody development deal, peeps into the Chan Zuckerberg Biohub, and offers advice to budding science entrepreneurs.

Bristol-Myers Squibb (BMS) broke records for the highest licensing fee with its potential $3.8 billion deal with Nektar Therapeutics last Wednesday.

Last week saw another string of high-value deals from the likes of AbbVie, Gilead and Merck & Co., welcome to our weekly round up.

Are you a scientist-entrepreneur with an outstanding start-up company based on scientific research? Or a university or research institution looking to showcase your most promising academic spin‑off?

We’ve returned to review the leading deals in biopharma after a spring break. Whilst we were away a number of significant deals took place.

Dealmaking has already started in earnest in 2018, with at least 20 deals signed in only the first two weeks. Many of these coincided with the annual JP Morgan conference that has just come to a close, and many of them involve big pharma.

Approvals and progress with nucleic-acid-based drugs continue to drive investment and dealmaking in the field.

A review of the first half of the year’s highest value partnerships, including mergers and acquisitions with the help of DealForma.

Approaches to slow or reverse aging have gained momentum in recent years, but the field is still in its infancy with hurdles to overcome, as illustrated by efforts to develop therapies that clear senescent cells.

We review the highest-value deals of the year with the help of DealForma.

Rare disease, neurology and immunology candidates are on big pharma’s shopping list this year.

Several recent billion-dollar merger and acquisition deals have expanded the range of services provided by leading molecular diagnostics companies.

Diseases of the central nervous system continue to catalyse dealmaking as companies search for new therapies to tackle some major unmet medical needs.

Dealmaking in the central nervous system disorder field has been dynamic in the past year despite COVID-19, and the market for therapies is set to expand in the next 5 years.

Funding for early-stage projects and global collaborations are aiming to breathe life into the fragile ecosystem for novel antibiotics.